Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 258-004-5 | CAS number: 52556-42-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 17 July 2012 - 13. September 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Environmental conditions
Healthy femal rats were housed by group of three in solid bottomed clear polycarbonates cages.
Temperature 19 - 25° C
Relative humidity 30 - 70 %
Food and drinking
Drinking water and foodstuff were supplied freely. Food was removed on D-1 and then redistributed 4 hours after the test item administration. - Route of administration:
- oral: gavage
- Vehicle:
- water
- Doses:
- 300 mg/kg bw/day and 2000 mg/kg bw/day
- No. of animals per sex per dose:
- 6 rats (female) per dose
- Control animals:
- no
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Mortality:
- No mortality occured in animals dosed at 300 mg/kg bw and 2000 mg/kg bw.
- Clinical signs:
- other: Dose: 300 mg/kg bw No clinical signs related to the adminsitration of the test item were observed during the study. Dose: 2000 mg/kg bw A decrease in spontaneous activity (3/) and piloerection (3/6) were noted at 1 hour post-dose.
- Gross pathology:
- The macroscopic examination of the animal at the end of the study did not reveal treatment related changes.
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The LD 50 of the test item is higer than 2000 mg/kg body weight by oral route in the rat.
In accordance with the OECD guideline No. 423, the LD50 cut off-of the test item may be considered higher than 5000 mg/kg body weight by oral route in the rat.
According to the criteria of classification , packaging and labelling of dangerous substances and preparation in accordance with the ECC Directives 67/548, 2001/59 and 99/45, the test item does not have to be classified. No symbol or risk phrase is required.
In accordance with the regulation EC No. 1272/2008 on classification, labelling and packaging of substances and mixtures, the test item does not have to be classified. No signal word or hazard satement is requird. - Executive summary:
The test item was administrated to a group of 6 female Sprague Dawley rats at a single dose of 300 mg/kg body weight ans then, to a group of 6 female sprague Dawley rats at the single dose of 2000 mg/kg body weight. The experimental protocol was established according to the official method as defined in the OECD guideline No. 423 dated December 17th, 2001 and the test method B.1 tris of the council regulation No. 440/2008.
No mortality occured in animals dosed at 300 mg/kg body weight.
No clinical signs related to the adminsitration of the test item were observed during the study.
No body weight evolution of hte animal remained normal throughout the study.
The macroscopic examination of the animal at the end of the study did not reveal treatment related changes.
No mortality occured in animals dosed at 2000 mg/kg body weight.
A decrease in spontaneous activity (3/) and piloerection (3/6) were noted at 1 hour post-dose.
No body weight evolution of hte animal remained normal throughout the study.
The macroscopic examination of the animal at the end of the study did not reveal treatment related changes.
In conclusion, the LD 50 of the test item is higer than 2000 mg/kg body weight by oral route in the rat.
In accordance with the OECD guideline No. 423, the LD50 cut off-of the test item may be considered higher than 5000 mg/kg body weight by oral route in the rat.
According to the criteria of classification , packaging and labelling of dangerous substances and preparation in accordance with the ECC Directives 67/548, 2001/59 and 99/45, the test item does not have to be classified. No symbol or risk phrase is required.
In accordance with the regulation EC No. 1272/2008 on classification, labelling and packaging of substances and mixtures, the test item does not have to be classified. No signal word or hazard satement is requird.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- The study is a GLP compliant and has Klimisch score 1.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 9 May - 10 July 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Elevage JANVIER (53840 Le Genest St Isle- France)
- Age at study initiation: 8 to 9 weeks
- Weight at study initiation: 245 to 271 g (males); 223 to 240 g (females)
- Housing: group, polycarbonate cages with steinless steel mesh lid
- Diet: M20-SDS ad libitum
- Water: ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 - 25 °C
- Humidity (%): 30 - 70%
- Photoperiod (hrs dark / hrs light): 12 - Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: dorsal area of the trunk
- % coverage: 10% of the body surface
- Type of wrap if used: gauze dressing
REMOVAL OF TEST SUBSTANCE
- Washing (if done): with distilled water
- Time after start of exposure: 24 hours
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 4.32 ml /kg, equal to 5235 mg/kg bw
the amount applied was calculated based on the density and the concentration of HAPS in the test item
VEHICLE
none - Duration of exposure:
- 24 hours
- Doses:
- 5235 mg/kg bw (equivalant to 2000 mg/kg compound)
- No. of animals per sex per dose:
- 5 rats/per sex
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: daily, weighing on day 0, 2, 7 and 14
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight - Statistics:
- mean and standard deviation of body weights
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 5 235 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: as aqueous solution
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other:
- Remarks:
- solid
- Mortality:
- no mortality observed
- Clinical signs:
- other: no systemic clinical sign was observed. Erythema was noted from 24 hours post-dose in all animals and was totally reversibel on day 7. Scabs were noted in all animals from 48 hours post-dose and remained on day 14 in all animals.
- Gross pathology:
- no treatment related changes
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The study is well performed and gives following results for the Endpoint:
LD 50 (dermal route) > 5235 mg/kg bw to testmaterial (aqueous solution)
LD 50 (dermal route) > 2000 mg/kg bw solid sodium 3-(allyloxy)-2-hydroxypropanesulphonate) - Executive summary:
At the request of the sponsor, the test item sodium 3-(allyloxy)-2-hydroxypropanesulphonate) (HAPS) was applied onto the intact skin of 10 Sprague Dawlley rats (5 males and 5 females) at the single dose of 5235 mg/kg body weight. The experimental protocol was established on the basis of the official method as defined in the OECD guideline No. 402 dated February 24th, 1987 and the test method B.3 of the Council regulation No. 440/2008 of 30 May 2008.
No mortality occured during the study.
No systemic clincal sign related to the administration of the test item was observed.
Erythrema was noted from 24 hours post-dose in all animals and was totally reversible on day 7. Scabs were noted in all animals from 48 hours post-dose and remained on day 14 in all animals.
The body weight evolution of the animals remained normal throughout the study.
The macroscopcal examination of the animals at the end of the study did not reveal treatment-related changes.
In conclusion, the LD 50 of the test item sodium 3-(allyloxy)-2-hydroxypropanesulphonate) (HAPS) as -aqueous solution -is higher than 5235 mg/kg bodyweight by dermal route in the rat.
In conclusion, the LD 50 of the test item sodium 3-(allyloxy)-2-hydroxypropanesulphonate) (HAPS) as -solid -is higher than 2000 mg/kg bodyweight by dermal route in the rat.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
According to Annex VIII 8.5.2 of regulation (EC) No 1907/2006 testing by the inhalation route is appropiated if exposure of humans via inhalation is unlikely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size. The test item is marketed in a solution, so the exposure of humans via inhalation is unlikely.
Justification for selection of acute toxicity – dermal endpoint
The study is a GLP compliant and has Klimisch score 1.
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.